Floating across the pond

A booming U.S. IPO market has some private European biotechs thinking about whether to make the leap over the pond. The decisions of two companies show that a U.S. listing may be advantageous for some - but not all - European companies.

Last month, Prosensa B.V. filed to raise up to $60 million in an IPO on NASDAQ. The Dutch company's lead program, drisapersen (PRO051, GSK2402968), is partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and is in Phase III testing to treat Duchenne muscular dystrophy (DMD). Data are expected 4Q13...